After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Yahoo Finance discussed the stock recently as it posted AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $42.23 and fluctuated between $42.49 as its day high and $42.13 as its day low. The current market capitalization of Cerevel Therapeutics Holdings Inc is $7.66B. A total of 1.18 million shares were traded on the day, compared to an average of 2.58M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, CERE has seen 7 BUY and 7 SELL insider trades, representing the acquisition of 188,130 and the disposition of 188,130 shares. Over the last 12 months, there were 27 BUYs and 22 SELLs from insiders. Insiders purchased 12,505,204 shares during that period but sold 1,605,279.
In the most recent transaction, COLES N ANTHONY sold 50,000 shares of CERE for 42.24 per share on Jan 02. After the transaction, the Director now owns 2,704 company shares. In a previous transaction on Dec 26, Sanchez Ramiro sold 10,000 shares at 42.47 per share. CERE shares that Chief Medical Officer owns now total 14,673.
Among the insiders who sold shares, DiPietro Kenneth disposed of 8,000 shares on Dec 22 at a per-share price of $41.45. This resulted in the Chief Human Resources Officer holding 24,663 shares of CERE after the transaction. In another insider transaction, ALTSCHULLER Susan sold 13,808 shares at $41.42 per share on Dec 20. Company shares held by the Chief Financial Officer now total 16,913.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, CERE has a high of $42.87 and a low of $19.59.
As of this writing, CERE has an earnings estimate of -$0.58 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.43 per share and a lower estimate of -$0.65. The company reported an EPS of -$0.63 in the last quarter, which was 3.10% higher than expectations of -$0.65.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CERE’s latest balance sheet shows that the firm has $565.69M in Cash & Short Term Investments as of fiscal 2021. There were $36.55M in debt and $42.54M in liabilities at the time. Its Book Value Per Share was $1.73, while its Total Shareholder’s Equity was $578.73M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CERE is Buy with a score of 3.36.
